FDA-approved indications for semaglutide-based weight management (Wegovy) require BMI ≥30 OR BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease).
Compounded semaglutide eligibility is determined by the licensed prescriber and may follow the same BMI thresholds or use clinical judgment for patients with related metabolic conditions. The legitimate medical use of compounded semaglutide should follow analogous clinical criteria — it should not be prescribed for cosmetic purposes in patients with normal weight. Always discuss eligibility with a licensed clinician.
NexLife is structured around clinical best practices for semaglutide. The same flat-rate pricing applies across the entire titration schedule ($145/mo on the 12-month plan from 0.25 mg through 2.4 mg), labs are included, MD/DO oversight is provided when clinically required, and Care360 coaching is built into every plan. See full NexLife review.
Compounded semaglutide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000
Citations supporting clinical and regulatory statements on this page. External links open in a new tab.
Verification methodology: /how-we-verify.html · Editorial accuracy: medically reviewed by Michael Baghdassarian, M.D. · Last reviewed 2026-06-01.